PDCD1 and non-small cell lung carcinoma: It has been also illustrated that PD-1 inhibitor plus chemotherapy could prolong the survival for advanced drive-gene-negative nonsquamous NSCLC patients: a previous study discloses that sintilimab plus chemotherapy could realize a median PFS of 8.9 months in advanced drive-gene-negative nonsquamous NSCLC patients (16).